卵巢上皮性癌伴腹水患者术前腹腔化疗的意义

Intraperitoneal chemotherapy before surgery in stage Ⅲc epithelial ovarian carcinoma with ascites

目的 :了解术前腹腔化疗对卵巢癌伴腹水患者的作用。方法 :1对 2 8例 c期卵巢癌伴腹水的患者术前行腹腔化疗 ,分别收集腹化前、腹化后 48h的腹水 ,分离腹化前后腹水中肿瘤相关淋巴细胞 (TAL ) ,用流式细胞仪检测其表型 ;2对上述 2 8例患者 ,同时采取腹化前及术后第 8天外周血检测 CA1 2 5 ;3另选 14例 c期卵巢上皮性癌伴腹水患者 ,术前不行腹化作对比 ,比较 CA1 2 5 的变化 ,比较肿瘤细胞减灭术的可行性。结果 :1腹化后腹水中 TAL 较腹化前有增加(P<0 .0 5 ) ;2腹化组患者肿瘤细胞减灭术的成功率高于对照组 (P<0 .0 5 ) ,且 CA1 2 5 降至正常的百分率 ,亦高于对照组(P<0 .0 5 )。结论 :术前腹腔化疗可能改善

Objective:To investigate the intraperitoneal chemotherapy before surgery on stage Ⅲc epithelial ovarian carcinoma with ascites.Methods 5-FU was repeatedly injected into the abdominal cavities of 28 patients with epithelial ovarian carcinoma for two times per day(QOD×2).The ascites were collected before and after intraperitoneal chemotherayp(IP).Flow cytometry was used to observe the phenotype of tumor associated lymphocytes(TAL).Venous blood was collected before IP and after operation to observe the changes of CA 125 .The other 14 cases with epithelial ovarian carcinoma were selected as control group to compare the changes of CA 125 and the feasibility of cytoreductive surgery in two groups.Reseults TAL in ascites collected after IP was higher than that before IP( P <0.05).The successful rate of cytoreductice surgery in injected group was higher than that in control group( P <0.05).The percentage of CA 125 ≤35 U/ml was higher in injected group than that in control group( P <0.05).Conclusions The intraperitoneal chemotherapy before surgery could improve the prognosis of stage Ⅲc epithelial ovarian carcinoma with ascites.